{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "marketState": "REGULAR", "regularMarketPrice": 2.5, "exchange": "FRA", "shortName": "G1 THERAPEUTICS  DL-,0001", "longName": "G1 Therapeutics, Inc.", "messageBoardId": "finmb_141112421", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketChangePercent": -4.2145557, "firstTradeDateMilliseconds": 1495692000000, "priceHint": 4, "regularMarketChange": -0.109999895, "regularMarketTime": 1683871215, "regularMarketDayHigh": 2.5, "regularMarketDayRange": "2.5 - 2.5", "regularMarketDayLow": 2.5, "regularMarketVolume": 588, "regularMarketPreviousClose": 2.61, "bid": 2.43, "ask": 2.49, "bidSize": 0, "askSize": 0, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 2.5, "averageDailyVolume3Month": 320, "averageDailyVolume10Day": 374, "fiftyTwoWeekLowChange": 0.30999994, "fiftyTwoWeekLowChangePercent": 0.14155248, "fiftyTwoWeekRange": "2.19 - 16.91", "fiftyTwoWeekHighChange": -14.41, "fiftyTwoWeekHighChangePercent": -0.8521585, "fiftyTwoWeekLow": 2.19, "fiftyTwoWeekHigh": 16.91, "earningsTimestamp": 1683117000, "earningsTimestampStart": 1690893000, "earningsTimestampEnd": 1691411400, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -2.34, "epsForward": -3.63, "epsCurrentYear": -3.63, "priceEpsCurrentYear": -0.6887052, "sharesOutstanding": 51660500, "bookValue": 1.335, "fiftyDayAverage": 2.7156, "fiftyDayAverageChange": -0.21560001, "fiftyDayAverageChangePercent": -0.07939314, "twoHundredDayAverage": 7.378165, "twoHundredDayAverageChange": -4.878165, "twoHundredDayAverageChangePercent": -0.6611624, "marketCap": 132760496, "forwardPE": -0.6887052, "priceToBook": 1.8726591, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "1.7 - Buy", "tradeable": false, "cryptoTradeable": false, "symbol": "G1H.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "700 Park Offices Drive", "address2": "Suite 200", "city": "Research Triangle Park", "state": "NC", "zip": "27709", "country": "United States", "phone": "919 213 9835", "fax": "919 741 5830", "website": "https://www.g1therapeutics.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor can protect bone marrow and reduce hematologic adverse events (AEs), as well as improve emerging treatments through myeloprotection which improve patients' overall anti-tumor immune responses combination with the antibody-drug conjugate; and treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.", "fullTimeEmployees": 170, "companyOfficers": [{"maxAge": 1, "name": "Mr. John E. Bailey Jr.", "age": 57, "title": "CEO, Pres & Director", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": {"raw": 1060200, "fmt": "1.06M", "longFmt": "1,060,200"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Mark A. Velleca M.D., Ph.D.", "age": 58, "title": "Sr. Advisor & Director", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": {"raw": 245000, "fmt": "245k", "longFmt": "245,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Mark  Avagliano", "age": 46, "title": "Chief Bus. Officer", "yearBorn": 1976, "fiscalYear": 2022, "totalPay": {"raw": 628537, "fmt": "628.54k", "longFmt": "628,537"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. John W. Umstead V", "age": 37, "title": "Chief Financial Officer", "yearBorn": 1985, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Terry L. Murdock", "age": 62, "title": "Chief Operating Officer", "yearBorn": 1960, "fiscalYear": 2018, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. William C. Roberts", "age": 53, "title": "VP of Investor Relations & Corp. Communications", "yearBorn": 1969, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Alexander D. Smith M.S.", "title": "VP of Technical Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. James Stillman Hanson", "age": 50, "title": "Gen. Counsel & Corp. Sec.", "yearBorn": 1972, "fiscalYear": 2018, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Jay C. Strum Ph.D.", "age": 58, "title": "Chief Scientific Officer", "yearBorn": 1964, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Evan  Hicks M.B.A.", "title": "VP of Marketing", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}